ABSTRACT
The intersection of intellectual property rights and public health represents a critical area of legal and policy discourse in India, particularly in relation to access to essential medicines. With the implementation of the TRIPS Agreement, India transitioned from a process-patent regime to a product-patent system in pharmaceuticals, significantly reshaping the legal framework governing drug innovation and distribution.
While patents are essential for promoting research and development and encouraging pharmaceutical innovation, they often result in higher drug prices, thereby limiting accessibility for a large segment of the population. This study examines the impact of pharmaceutical patenting on affordability, availability, and the role of India’s robust generic drug industry, which has been instrumental in ensuring low-cost medicines both domestically and internationally.
KEYWORDS – INTELLECTUAL PROPERTY RIGHTS (IPR) , TRIPS agreements , Right to
health , drug pricing .
Chapter 1 – INTRODUCTION
1.1 BACKGROUND OF THE STUDY
The development of intellectual property rights, particularly in the pharmaceutical sector, has played a crucial role in shaping global healthcare systems. Patents are intended to reward innovation by granting exclusive rights to inventors, thereby encouraging investment in research and development of new medicines.
1.2 SIGNIFICANCE OF THE STUDY
The significance of this study lies in examining how India has attempted to address this complex challenge through its legal and policy framework. Provisions such as compulsory licensing and Section 3(d) of the Patents Act have been introduced as safeguards to prevent the misuse of patent rights and to ensure that medicines remain accessible to the public.
1.3 LITERATURE REVIEW
The issue of intellectual property rights and access to medicines has been widely examined by scholars, policymakers, and international organizations over the years. Early literature highlights the inherent conflict between patent protection and public health, particularly in developing countries. Carlos M. Correa (2000) in his seminal work Intellectual Property Rights, the WTO and Developing Countries argued that stringent patent regimes under the TRIPS Agreement could adversely affect access to medicines by increasing drug prices and limiting generic competition.
1.4 SCOPE AND OBJECTIVE OF THE STUDY
The present study focuses on analysing the impact of intellectual property laws, particularly pharmaceutical patents, on access to medicines in India. It examines the legal framework governing patents under the Patents Act, 1970 (as amended in 2005), in light of international obligations such as the TRIPS Agreement. The study explores key provisions like Section 3(d) and compulsory licensing, which aim to balance patent protection with public health concerns.
To examine the concept of intellectual property rights .
To analyse India’s patent regime thoroughly .
To evaluate the role of international agreements, especially the TRIPS Agreement, in shaping India’s patent regime.
1.5 RESEARCH METHODOLOGY
The present study adopts a systematic and structured research methodology to analyse the impact of intellectual property laws on access to medicines in India. The methodology is primarily doctrinal in nature and is supported by analytical and descriptive approaches
CHAPTER 2 – INDIA’S PATENT REGIME
India’s patent regime, primarily governed by the Patents Act, 1970, represents a distinctive attempt to balance the competing interests of innovation, economic growth, and public health. Over the years, particularly after the 2005 amendment aligning it with the TRIPS Agreement, India has developed a framework that is often described as “public health–oriented.”
While this model has been widely appreciated for safeguarding access to medicines, it has also faced criticism for allegedly weakening patent protection and discouraging innovation. A critical analysis reveals both strengths and structural challenges within this regime.
The Indian patent regime is not without its challenges. One of the primary criticisms is
that stringent patentability criteria, especially under Section 3(d), may discourage pharmaceutical innovation and foreign investment.
CHAPTER 2 – STRENGTHS OF EVERGREENING OF PATENTS
Evergreening of patents is a significant issue in pharmaceutical law, referring to the practice by which patent holders attempt to extend the duration of their monopoly by making minor modification to existing drug rather than developing new drug.
The concept of evergreening directly affects the balance between innovation and public health. While patent protection is intended to reward genuine innovation, evergreening allows pharmaceutical companies to maintain market exclusivity without significant advancement in medical science.
The challenge, therefore, lies in distinguishing between genuine innovation and strategic modifications aimed at extending patent protection. This requires robust examination procedures, technical expertise, and clear legal standards. The role of patent offices and the judiciary becomes
crucial in ensuring that decisions are made based on scientific evidence and public interest considerations.
CHAPTER 3 – ISSUES IN IMPLEMENTATION OF SECTION 3(d)
Section 3(d) of the Patents Act, 1970 is a distinctive provision aimed at preventing evergreening of pharmaceutical patents by requiring proof of enhanced therapeutic efficacy for new forms of known substances. While it has been widely praised as a pro-public health safeguard, its
implementation has faced several legal, technical, and practical challenges. These issues often arise from the complexity of interpreting “enhanced efficacy” and balancing strict patentability standards with the need to encourage innovation.
The provision has also been criticised for creating uncertainty in the pharmaceutical industry. Multinational companies often argue that the strict standards under Section 3(d) make it difficult to predict whether a patent application will be granted. This uncertainty can affect investment decisions, research planning, and market entry strategies. Companies may be hesitant to invest in incremental innovations if there is a high risk of rejection, even when such innovations could improve patient outcomes.
The implementation of Section 3(d) is also influenced by international pressures and trade relations. Developed countries and pharmaceutical corporations have often criticised the provision as being overly restrictive and inconsistent with global intellectual property standards. Although India justifies Section 3(d) as being compliant with the flexibilities allowed under the TRIPS Agreement, these external pressures can impact policy discussions and negotiations at the international level.
CHAPTER 4 – CHALLENGES IN COMPULSORY LICENSING MECHANISM
Compulsory licensing is a vital public health safeguard under the Patents Act, 1970, designed to ensure access to affordable medicines in situations where patent rights may hinder availability or pricing. However, despite its importance, the practical implementation of compulsory licensing in India faces several legal, procedural, economic, and international challenges.
These issues limit its frequent and effective use, making it more of an exceptional remedy rather than a routinely applied mechanism. One of the primary challenges is the complex and time-consuming procedural framework involved in obtaining a compulsory license.
Another significant challenge is the limited use of compulsory licensing in practice. Despite the legal provisions, India has granted very few compulsory licenses, with Natco Pharma Ltd. v. Bayer Corporation being the most prominent example. The rarity of such licenses suggests that the mechanism is not being fully utilized, possibly due to procedural hurdles, fear of litigation, and concerns about international repercussions. This underutilisation reduces the potential impact of compulsory licensing as a tool for improving access to medicines.
Developed countries and multinational pharmaceutical companies often view compulsory licensing as a threat to intellectual property rights and innovation. As a result, countries like India may face diplomatic and trade pressures when they attempt to exercise this flexibility under the TRIPS Agreement. Such pressures can discourage governments from issuing compulsory licenses, even when public health needs justify their use.
The interpretation of key terms within the compulsory licensing framework also presents challenges. Concepts such as “reasonable requirements of the public,” “affordable price,” and “working of the patent” are not precisely defined, leading to ambiguity and potential disputes. This lack of clarity can result in inconsistent decisions and legal uncertainty, making it difficult for applicants to predict outcomes and plan accordingly.
CHAPTER 5 – IMPACTS OF MULTINATIONAL PHARMACEUTICAL COMPANIES
Multinational pharmaceutical companies (MNCs) have a profound impact on India’s patent regime, drug pricing, and overall access to medicines. These corporations, often holding patents for innovative drugs, operate in a complex global market where intellectual property rights, profitability, and public health priorities frequently intersect.
One major impact of MNCs is on drug pricing. Patented medicines introduced by multinational companies are often priced significantly higher than locally produced generics. This high cost can make essential drugs unaffordable for large segments of India’s population, particularly those relying on out-of-pocket healthcare expenditures.
MNCs also influence patent policy and litigation trends in India. Many multinational firms actively seek patent protection for both major and incremental innovations, sometimes engaging in evergreening practices to extend monopolies. While these actions are legally permissible in many countries, India’s Section 3(d) has often been invoked to limit such practices, as seen in the landmark Novartis AG v. Union of India. These legal confrontations highlight the tension between global pharmaceutical interests and domestic public health objectives.
CHAPTER 6 – LEGAL FRAMEWORKS AND LANDMARK JUDGEMENTS
The legal framework of pharmaceutical patents in India represents a carefully crafted balance between international commitments and domestic public health needs. By aligning with global agreements like TRIPS while incorporating safeguards such as Section 3(d) and compulsory licensing, India has created a unique model of patent governance. This model not only promotes innovation but also ensures access to essential medicines, reflecting a broader commitment to social welfare and equitable healthcare in both national and international contexts.
The judiciary in India has played a transformative role in protecting access to medicines by interpreting constitutional provisions in a manner that prioritises public health. Through expansive readings of Article 21 of the Constitution of India, courts—especially the Supreme Court of India—have established that the right to life includes the right to health, which necessarily encompasses access to essential medicines. This judicial approach has ensured that legal and policy frameworks governing pharmaceuticals are aligned with the broader objective of safeguarding human dignity and well-being.
Consumer Education and Research Centre v. Union of India, where the Supreme Court explicitly recognized the right to health and medical care as a fundamental right under Article 21. The Court emphasized that the state has a constitutional obligation to provide healthcare facilities to workers and ensure safe working conditions. This case marked a significant step in affirming the state’s responsibility in protecting public health.
Directive Principles of State Policy (DPSPs) under Part IV of the Constitution of India also support the right to health. Provisions such as Articles 39(e), 41, and 47 impose a duty on the state to improve public health, ensure adequate nutrition, and provide medical assistance. Although these principles are not enforceable in courts, they guide the state in formulating policies aimed at promoting health and well-being.
The judiciary has also supported the use of TRIPS flexibilities to promote access to medicines. By recognizing the importance of provisions such as compulsory licensing, Indian courts have upheld the government’s authority to intervene in cases where patented drugs are not available at reasonable prices. These interpretations are consistent with international principles laid down in
the Doha Declaration on TRIPS and Public Health, which affirms the right of countries to prioritize public health over strict patent enforcement.
CHAPTER – 7 FINDINGS , ANALYSIS AND RECOMMENDATIONS
Key Findings of the Study Patent Regulation and Innovation Control – India’s patent system, particularly Section 3(d), effectively prevents minor modifications from being patented, protecting public health while encouraging genuine innovation.
The analysis of India’s pharmaceutical patent regime reveals a complex interplay between innovation incentives and public health objectives. Patents are designed to encourage pharmaceutical research and development by granting exclusive rights to inventors for a limited period. However, in the context of essential medicines, These exclusive rights can have a dual effect: while they promote innovation, they also have the potential to restrict access by raising drug prices and delaying the entry of generic alternatives. The Indian experience demonstrates that carefully calibrated legal provisions, such as Section 3(d) of the Patents Act, are crucial in mitigating these negative effects while maintaining an environment conducive to innovation.
Strengthen Enforcement of Section 3(d) – Establish specialized patent tribunals or fast- track courts with expertise in pharmaceutical IP to reduce delays in litigation and ensure consistent interpretation of the law.
Simplify Compulsory Licensing Mechanism – Provide clear guidelines, streamline procedural requirements, and create awareness programs for domestic manufacturers to effectively use compulsory licensing for essential drugs.
Enhance NPPA Monitoring and Coordination – Implement real-time price tracking, strengthen state-level coordination, and enforce stricter penalties for violations to ensure affordable access to medicines.
CONCLUSION
In conclusion, the research demonstrates that while legal and policy frameworks provide a vital foundation, their success depends on holistic implementation, stakeholder participation, and adaptive strategies that respond to changing contexts. Sustainable progress requires bridging the gap between theory and practice, strengthening institutional capacity, and promoting social awareness. By adopting an integrated approach that combines legal, social, and technological tools, policymakers and practitioners can address existing challenges effectively while anticipating future developments. Ultimately, the study underscores that meaningful change is achieved not solely through legislation, but through a concerted, inclusive, and adaptive effort that aligns policy intent with societal realities.
The study also uncovers significant variations in the effectiveness of institutional mechanisms, reflecting disparities in capacity, expertise, and strategic focus. Certain agencies or institutions perform exceptionally well in specific contexts, yet these successes are rarely standardised or scaled, resulting in uneven outcomes across regions and sectors. This highlights the importance of developing uniform protocols and capacity-building initiatives that can harmonize practices and strengthen accountability. Moreover, the findings suggest that inter-institutional coordination remains weak, often leading to duplication of efforts or contradictory interventions, which diminishes overall efficacy and public confidence in governance structures.
REFRENCES
National Pharmaceutical Pricing Authority (NPPA) Official Website: https://www.nppaindia.nic.in
Knowledge Ecology International: https://www.keionline.org Medicines Patent Pool: https://medicinespatentpool.org Novartis AG v. Union of India & Others, (2013) 6 SCC 1.
Roche Products Ltd. v. Cipla Ltd., 2010 (India Patent Case).
Government of India, Ministry of Health and Family Welfare. National Pharmaceutical Pricing Authority Annual Report, 2022.
MSF (Médecins Sans Frontières). Untangling the Web of Antiretroviral Price Reductions, 2021 Edition.
